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take into account confidential discounts under patient access schemes. Finally, 
the threshold probability of cost effectiveness seems to lie between 30% and 60%.
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Objectives: Multi criteria decision analysis (MCDA) aims to support decision-mak-
ing where decisions are based on multiple criteria. In disciplines like engineering 
and environmental policy, MCDA is widely accepted and routinely used. The use of 
MCDA in HTA priority setting and reimbursement decisions is growing, but mostly 
limited to research projects. A factor that might influence acceptance is a perceived 
difficulty to value an MCDA’s outcome when its inputs and outputs contain uncer-
tainties. When this is the case, decision makers might not feel confident in accept-
ing or rejecting its outcome. The objective of this study is to systematically review 
how parameter uncertainty is taken into account in value-based MCDA methods 
in general, and to discuss which of the approaches is appropriate for the setting of 
reimbursement decision making in health care. MethOds: A systematic literature 
review was conducted using the Scopus database. Found abstracts were categorized 
by MCDA method used. Then, themes and families of methods were identified by 
two independent reviewers. Selected full text articles were read to identify methodo-
logical details. Results: The search strategy identified 635 abstracts, mostly from 
engineering and environmental journals and only 1.6% in health journals. Identified 
themes were fuzzy set theory (n= 223), probabilistic framework (n= 68), deterministic 
sensitivity analysis (n= 140), Dempster-Shafer theory (n= 14), Bayesian framework 
(n= 7) and Grey theory (n= 8). A large number of papers considered the Analytic 
Hierarchy Process in combination with fuzzy set theory (n= 155). cOnclusiOns: 
In the health literature there is little attention for parameter uncertainty. Methods 
to deal with parameter uncertainty in MCDA must strike a balance between com-
prehensibility and understandability. Several complex methods are developed for 
parameter uncertainty, but there seems to be a gap between the theory and the 
implementation of those methods. For simple applications, methods like deter-
ministic sensitivity analysis are likely to be sufficient.
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Objectives: To investigate quantitatively, if and to which extent the German 
Arzneimittelmarkt-Neuordnungs-Gesetz (AMNOG) delays market access of phar-
maceuticals. Secondary objective was to potentially identify predictors for access 
delay. MethOds: All AMNOG assessment procedures that were completed at the 
level of the joint federal committee (G-BA) by May 15 2013 were included (web-
site www.g-ba.de). Time delay to dossier submission was calculated between the 
approval date of the European Medicines Agency (EMA) and the mandatory AMNOG 
dossier submission date. Submission date usually occurs when pharmaceuticals are 
made available and is decided upon by the manufacturer. We also included in the 
analysis the ordinal level classification and evidence certainty level for each product 
as assessed by Institute for Quality and Efficiency in Health Care (IQWiG) and G-BA 
as well as the ATC code. Results: In n= 17 (49%) of N= 35 investigated pharmaceu-
ticals a small time delay greater than 1.1 months (which is usually feasible) after 
EMA approval was observed, but only 20% had a delay > 2 months. A negative cor-
relation existed between the amount of time delay to dossier submission and the 
benefit level outcome as assessed by IQWIG (r= -0.258, n.s.) and the final result by 
G-BA (r= -0.484, p= 0.003). Benefit assessment outcomes between IQWiG and G-BA 
were correlated moderately with r= 0.442 (p< 0.008). For both, IQWiG (r= 0.841) and 
G-BA (r= 0.773) certainty of evidence correlated highly with the benefit level out-
come. cOnclusiOns: This analysis highlights the impact of AMNOG on the market 
access of pharmaceuticals in Germany. Overall, only small time delays existed for 
most products. Time delay in market access correlated significantly with a nega-
tive assessment of additional benefit by G-BA. Evidence certainty clearly correlated 
with benefit outcomes.
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Objectives: In Scotland, drug reimbursement is predominantly based on cost-
effectiveness in contrast to the corresponding German AMNOG process. The study 
compares the reimbursement and pricing process in Germany (AMNOG), as reformed 
in 2011, and Scotland (SMC) based on reimbursement assessments. MethOds: All 
AMNOG and SMC appraisal decisions made in 2011-2012 were identified. Matching 
AMNOG-SMC cases were found and compared in terms of final appraisal decision 
and rationale. Results: For 2011-2012, forty-one AMNOG cases over 60 subgroups 
and 193 SMC cases were identified; twenty five matching cases were compared 
as these were assessed by both organizations. Regarding these 25 cases, AMNOG 
deemed ten cases demonstrated no additional benefit, in two cases the additional 
benefit was unquantifiable, slight benefit was acknowledged in seven cases and 
in six there were significant benefits. Based on the benefit assessment the negoti-
ated price rebates ranged from 4.7% to 70.7% based on manufacturer set price. No 
restrictions to subgroups were opposed to any reimbursement decision. The SMC 
reimbursed 18 products (72%), of which four were restricted to a certain population 
due to cost-effectiveness. SMC rejected 7 cases (28%) based on weak economic evi-
Objectives: To investigate the problem of pricing and reimbursement of pharma-
ceuticals in Iran. A large amount of country’s Health care expenditures, including 
insurance organizations’ expenses, are spent for pharmaceutical products. However, 
the high amount of capital spent by the users for purchasing pharmaceuticals 
indicates a serious flaw in the system. As will be shown, this flaw is due to the struc-
tures, policies, and regulations of Iranian medical insurance system. MethOds: 
This is a descriptive study and, therefore, ethnographic site and fieldwork were used 
as the main source of information. Furthermore, information on the Internet and 
several Iranian online databases has been used for comparison purposes. Results: 
Ministry of Health and Medical Education (MOHME) is the main responsible body 
for pharmaceuticals in Iran. However, different government organizations such 
as Ministry of Commerce, the Central Bank of Iran, and National Industries 
Organizations are involved in policy-making in this sector. MOHME decides how 
to allocate governmental supports and foreign currency quotas, to various related 
industries. This is done due to the fact that MOHME decides which pharmaceuti-
cals should be covered and distributed in the country. However, prices are set by 
insurance organizations due to their bargaining power over MOHME. Insurance 
companies pay approximately 70-90% of the final price of a product. However, for 
purchasing expensive products, confirmation from insurance companies is needed. 
The reimbursed price is set at the level of the lowest priced equivalent on the mar-
ket. cOnclusiOns: These flaws and loopholes arise because of system’s negligence 
on research and development methods and, therefore, lack of standard regulations 
on reimbursement decisions and priority settings. Inflexible profit margins for dif-
ferent products with different unit costs, incomplete support for vulnerable groups 
and patients with chronic diseases, and absence of rational pharmaceutical usage 
campaigns can be named as other major problems.
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Objectives: Personalized health care (PHC) is a treatment model that customizes 
health care based on biomarker-based prediction of likely response. It is increas-
ingly being prioritized by politicians and payers—one recent example is the pub-
lished strategy plan by the German Federal Ministry of Education and Research. 
A key policy question remains whether health care systems and health tech-
nology assessment (HTA) bodies are adequately prepared evaluating these new 
treatment options. MethOds: Existing HTA evaluation methods for therapies in 
France, Germany, and the UK were reviewed with respect to the applicability to 
PHC products based on information provided by decision-making bodies and the 
literature. Results: Current HTA evaluation methods being applied to medical 
therapies, in general, need to be modified when applied to PHC. For example, tra-
ditional benefit evaluations that require randomized clinical trials are standard 
but cannot always be fulfilled in PHC. Furthermore, combined benefit assessments 
for typical PHC treatment—e.g., a pharmaceutical combined with a diagnostic 
test—lack experience about appropriate evaluation methods to use. Today, decison 
makers and manufacturers rarely make use of the opportunity to re-assess or for 
joint evidence generation. Finally, reimbursement for PHC is inflexible and does 
not fully reflect the value of targeting, including the reduction in uncertainty and 
greater appropriate use. Among these three, the UK seems the most open to PHC 
funding. HTA in France and Germany does not recognize the special economic and 
evidence features of PHC, though the French system is more open to innovative 
market access. cOnclusiOns: If the largest EU health care systems are to secure 
the full benefits of PHC, they will need to provide for full and flexible reimbursement 
for innovative technologies and services based on value. Currently, the importance 
of PHC by health care politicians is not being reflected in the evaluation tools or 
reimbursement methods being applied.
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Objectives: To analyse trends in reimbursement in Ireland to help in the planning 
of HTAs from an industry perspective. MethOds: A database of all NCPE deci-
sions and reimbursement for drugs from 2006 to April 2013 was developed from 
publically available NCPE reports and HSE websites. A descriptive analysis of the 
database was undertaken. Results: From 2006 to April 2013 37% of drugs were 
reimbursed without a HTA and 63% were recommended for HTA (N= 126). There 
were three HTAs undertaken in 2006 compared to 26 in 2012. High Tech (HT) drugs 
were more likely to attract a HTA compared to General Medical Services (GMS) drugs 
(83% vs. 51%). Of the HTAs completed, 57% resulted in a positive reimbursement 
recommendation within a median time from HTA submission to reimbursement 
of 7.9 months (min 3.9, max 16.3). The median time was 7.1 and 9.8 months for 
GMS and HT drugs respectively. Dominance almost perfectly predicted reimburse-
ment; 83% reimbursed. Of the ICERs in the north-east quadrant, 54% resulted in 
a positive reimbursement recommendation (average ICER around € 60,000/QALY). 
The cost per QALY for those not reimbursed in this quadrant was almost twice this 
at around € 110,000. Finally, the average probability of cost effectiveness for reim-
bursed and non-reimbursed drugs were 60% and 30% respectively. cOnclusiOns: 
Companies can expect more requests for HTAs especially for HT drugs. When HTAs 
are requested the probability of success is around 60% with an expected timeline 
of 8 months from submission to launch. Budget impact does have an important 
role to play as dominance is a strong predictor of reimbursement. The average cost 
per QALY for reimbursed drugs is above the € 45,000/QALY threshold but does not 
